MedImmune, a global biologics R&D arm of AstraZeneca, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, US-based oncology firm focusing on genetic and epigenetic drivers of cancer.
As part of the deal, a Phase I/II trial will be conducted to evaluate the safety and efficacy of MedImmune's durvalumab (MEDI4736) in combination with Mirati's mocetinostat in patients with non-small cell lung cancer (NSCLC), with the potential to explore additional indications in the future.